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WS16.5 Selective ion-ﬂow mass spectrometry (SIFT-MS) analysis
of exhaled breath as a non-invasive determinant of
Pseudomonas aeruginosa infection in CF patients
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J.C. Davies1,2. 1Royal Brompton & Hareﬁeld NHS Foundation Trust, Paediatric
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Objectives: Pseudomonas aeruginosa (Pa) produces volatile organic compounds
(VOCs) such as hydrogen cyanide (HCN) and 2-AA. We hypothesised that exhaled
breath analysis might allow discrimination of CF patients with (CF+Pa) and without
Pa (CF−Pa).
Methods: 100 adults (44 CF+Pa, 29 CF−Pa and 27 controls) provided single
exhalation breaths into Nalophan bags. Quantiﬁcation of 15 VOCs was performed
using SIFT-MS. Results are presented as (median parts-per-billion by volume
[range]).
Results: 2-AA was higher in CF+Pa than CF−Pa (3.7 [1.2−6.0] vs. 1.9 [0.0−3.3],
p< 0.01). Dimethyl disulphide (DMDS) was also higher in CF+Pa (81.1 [42.0–
149.6] vs. 45.4 [22.9–74.4], p< 0.05). When combined with 2-AA, area under
ROC curve was 0.822.
Counter to our sputum data, there was no difference in HCN between CF+Pa and
CF−Pa (9.0 [5.5–12.8] vs. 9.1 [5.5–12.6], n/s) or between all CF patients and
controls (9.1 [5.5–12.6] vs. 7.8 [4.8–12.7], n/s). Our early in vitro data showed
decreased butanol above Pa cultures, suggesting consumption. This was replicated
in breath with lower levels in CF+Pa vs. CF−Pa (38.6 [26.3–71.9] vs. 64.0 [30.1–
112.8], p< 0.05). Of VOCs likely to be of host origin, isoprene was increased in
CF vs. controls (89.4 [62.3–159.0] vs. 68.5 [47.6–85.8], p< 0.01) with no difference
between CF+Pa vs. CF−Pa.
Conclusions: 2-AA is a potential biomarker of Pa infection but clinical utility is
uncertain. DMDS and butanol also show promise. Mouth-exhaled HCN assessed
by SIFT-MS does not appear to fulﬁl its promise as a Pa biomarker. This study
provides proof-of-concept for development of a non-invasive screening tool for
bacterial infection in CF though a clinically applicable test remains some way off.
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Objectives: Although Prevotella spp. are frequently detected as members of the CF
airway microbiome, current techniques for their identiﬁcation and typing are labour
intensive and reliant on 16S rRNA gene sequencing. This study aimed to determine
if Matrix Assisted Laser Desorption Ionization-Time Of Flight (MALDI-TOF) is a
suitable alternative for the identiﬁcation and typing of clinical Prevotella sp.
Methods: MALDI-TOF was performed on clinical isolates (n = 67), from a range
of sources [CF sputum (n = 27), Non-CF isolates (n = 39)]. Isolates were previously
identiﬁed as Prevotella sp. by sequencing of the 16S rRNA gene, and typed by Pulse
ﬁeld gel electrophoresis (PFGE) and Random ampliﬁed polymorphic DNA (RAPD).
PFGE and RAPD proﬁles were analysed by dendrograms (UPGMA analysis) and
isolates grouped which had >55% (PFGE) or >50% (RAPD) homology.
Results: Of 67 isolates tested, 46 (69%) were identiﬁed by MALDI-TOF as
Prevotella sp., 5/67 (7%) were identiﬁed as other bacterial species and 8/67 (12%)
failed to grow. A further 8/67 (12%) isolates could not be identiﬁed by MALDI-TOF.
MALDI-TOF groupings were concordant with speciation by 16S rRNA analysis.
However, genotyping by PFGE and RAPD showed little proﬁle similarity between
isolates of the same species, with individual species represented by two or more
PFGE or RAPD strain types.
Conclusion: MALDI-TOF is a useful method to rapidly identify Prevotella isolates
at the species level, with further work required to determine its suitability as a
genotyping method.
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WS16.7 Use of nrdA sequence clustering for species-level
identiﬁcation of Achromobacter spp. from CF patients in
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Objectives: Our role as a national reference laboratory is to support hospital labora-
tories in the accurate identiﬁcation of bacteria isolated from CF patients. Previously
our use of the gyrB gene to identify CF pathogens revealed the existence of novel
clusters within the Achromobacter genus. Concurrently in 2012 publications by
other groups named eight novel species (A. dolens, A. insuavis, A. mucicolens,
A. pulmonis, A. spiritinus, A. anxifer, A. aegrifaciens and A. animicus) and showed
that nrdA allelic variation could be used for species-level identiﬁcation within this
genus.
Methods: nrdA sequencing was used to estimate the prevalence of these novel
species among UK CF patients.
Results: Between June and December 2013 nrdA sequences were determined for 92
Achromobacter isolates from 68 patients and 27 hospitals. Forty patients harboured
A. xylosoxidans, while A. insuavis and A. dolens were the next most prevalent
species, infecting nine and six patients, respectively. The remaining thirteen patients
harboured A. marplatensis, A. ruhlandii and genogroups 3 and 13. Repeat isolates
from patients belonged to the same species. An additional small sequence cluster
was found suggesting yet another novel species with relevance to CF. Pulsed-ﬁeld
gel electrophoresis revealed evidence of A. xylosoxidans cross-infection in three
hospitals but, conversely, showed that four paediatric patients from another hospital
harboured distinct A. insuavis strains, ruling out cross-infection in this instance.
Conclusion: In summary, nrdA permitted accurate species resolution, highlighted
the dominance of A. xylosoxidans among UK CF patients, and facilitated cross-
infection analyses.
WS16.8 Whole genome sequencing provides evidence of
within-patient evolution and adaptation to the lung of
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Aims: Mycobacterium abscessus is an emerging cause of chronic infection in
patients with cystic ﬁbrosis. Our aim was to look for evidence of within-patient
evolution of M. abscessus using whole genome sequencing.
Methods: Whole genome sequencing was performed on 155 isolates of M. ab-
scessus from 22 patients. Genetic diversity across the whole genome was analysed.
Colony morphology was documented and antibiotic susceptibility testing performed
on a subset. Clinical data was collected − including treatment regimens, lung
function (FEV1), and markers of systemic inﬂammation (C-reactive protein).
Results: Genetic diversity (pairwise SNP distance) between isolates from the same
individual, and genetic diversity within each sample (measured by number of
minority variants), both increased with the duration of infection (r2 = 0.78, p-value =
0.0007; r2 = 0.72, p-value <0.0001 respectively).
We found that genetic diversity correlated with bacterial load (using time to liquid
culture positivity as a surrogate) and that these correlated with clinical exacerbations
(demonstrated by changes in CRP and/or FEV1).
We saw phenotypic evidence of within-sample diversity (morphotype and antibiotic
susceptibility) and found genetic heterozygosity within associated genes. We also
detected convergent evolution of M. abscessus isolated from different individuals
(accumulation of non-synonymous SNPs) in a number of genes thought to control
virulence.
Conclusion: We have demonstrated for the ﬁrst time that the genetic diversity of
M. abscessus increases over the course of infection and may play an important role
in the development of antibiotic resistance and modulation of virulence.
